Core Insights - Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., received a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation [1] - This score is the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year's report [1] Company Performance - The AMR Benchmark evaluates pharmaceutical companies' efforts in combating antimicrobial resistance, highlighting Innoviva's commitment to infectious disease therapeutics [1]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a substantial shift in the global economy driven by AI innovation [2] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is believed to be redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4] - Prominent investors, including Bill Gates and Warren Buffett, recognize AI as a significant technological advancement with the potential for substantial social benefits [8] Market Trends - The AI ecosystem is expected to reshape business, government, and consumer operations globally, indicating a shift in market dynamics [2] - The enthusiasm for AI is reflected in the investments and partnerships of major tech companies, highlighting the competitive landscape [6][8]

Core Thesis - Innoviva, Inc. presents a compelling investment opportunity as it transitions from a royalty-based revenue model to a growing commercial pharmaceutical platform, currently undervalued by the market [2][5]. Financial Overview - As of February 11th, Innoviva's share price was $22.48, with trailing and forward P/E ratios of 13.54 and 10.83 respectively [1]. - The company historically generated approximately $400 million in annual revenue and $364 million in free cash flow, primarily from GSK-licensed drugs [2]. Business Transformation - Innoviva is building a new commercial operation, the Innoviva Specialty Therapeutics (IST) platform, which focuses on hospital-based, critical-care, and infectious disease treatments [3]. - The IST platform currently generates nearly $150 million in revenue, accounting for about 40% of total revenue, with a year-over-year growth rate of 46% [3]. Revenue and Cash Flow Potential - Once revenues exceed breakeven at approximately $150 million, incremental revenue is expected to convert into over 60% free cash flow, indicating strong operating leverage [3]. - The market values Innoviva primarily on its remaining royalty stream of around $1.35 billion, effectively pricing the new commercial platform for free, creating an asymmetric risk/reward opportunity [4]. Strategic Positioning - Innoviva's balance sheet is strong, with significant liquidity that supports the transition without jeopardizing operations [4]. - Key catalysts for growth include the continued expansion of core IST drugs, conversion of revenue into sustainable free cash flow, and potential interest from larger pharmaceutical companies as a takeover target [5]. Market Valuation - With a current market capitalization of $1.4 billion, investors benefit from robust downside protection from royalties while also participating in the upside of a scaling commercial business [5]. - The fair value estimate for Innoviva's shares is around $35, indicating significant upside potential [5].

Core Insights - Innoviva is evolving its business model from a royalty-focused company to a diversified entity with three main components: a respiratory royalty stream, a growing specialty therapeutics platform, and a strategic healthcare investment portfolio valued at over $600 million [3][6]. Strategic Healthcare Assets - The strategic healthcare investment portfolio is currently valued at over $600 million, with recent momentum driven by clinical progress at Armata [1]. Innoviva Specialty Therapeutics (IST) - IST generated nearly $120 million in U.S. sales last year and is projected to achieve at least $150 million in sales this year, marking the third consecutive year of 50% annual growth [2][6]. Royalty Business - The royalty portfolio from GSK-marketed respiratory products, Breo and ANORO, generated $250 million in gross revenue last year, demonstrating durability and resilience [3][6]. Financial Position and Capital Allocation - The company holds a strong cash position of over $500 million and has announced a $125 million share repurchase program, focusing on IST profitability and disciplined external investments [5][7][8]. Upcoming Catalysts - Key near-term catalysts include Armata's planned Phase III study, commercial launches for ZEVTERA and NUZOLVENCE, and continued product momentum for GIAPREZA and XACDURO, which could drive upside in 2026 [4][17]. Product-Level Trends - GIAPREZA is expected to generate $72 million in U.S. net sales in 2025, while XACDURO is projected to achieve $33 million, representing over 100% year-over-year growth [14][15]. ZEVTERA and NUZOLVENCE Updates - ZEVTERA has received J-code designation and New Technology Add-on Payment status to enhance reimbursement, while NUZOLVENCE is set for commercialization in the second half of the year [12][13]. Long-Term Opportunities - The total addressable market for NUZOLVENCE could reach $500 million if resistance trends align with expectations, indicating significant growth potential [16].

Company Overview - Innoviva was originally formed to manage royalty revenues from products developed with and licensed to GSK [1] - The company has evolved to create and drive shareholder value through three main components [1] Revenue Streams - The first component is the royalty business from two respiratory assets, Breo and Anoro, generating $250 million in gross royalty revenue last year [1] - The second component is the Specialty Therapeutics business, which delivered almost $120 million in U.S. sales last year and is expected to generate at least $150 million this year [2]

Innoviva Conference Call Summary Company Overview - Innoviva was originally formed to manage royalty revenues from products developed with GSK, focusing on creating shareholder value through diversified business areas [1] - The company consists of three main components: 1. Royalty business from respiratory assets Breo and ANORO, generating $250 million in gross royalty revenue last year [2] 2. Specialty therapeutics business (Innoviva Specialty Therapeutics, IST), which delivered nearly $120 million in US sales last year and is expected to generate at least $150 million this year [2] 3. A diversified portfolio of strategic healthcare assets valued at over $600 million [3] Financial Performance - Innoviva reported strong Q4 earnings, showcasing growth across all business segments and strong momentum heading into 2026 [3] - IST business achieved its best quarter ever with $34 million in U.S. sales, marking three consecutive years of 50% annual growth [4] - The royalty business outperformed expectations, contributing to overall resilience [4] Capital Allocation Strategy - Innoviva has a cash position of over $500 million, allowing for attractive opportunities for value creation through capital deployment [6] - Plans include investing in organic growth for IST, supporting strategic healthcare assets, and evaluating new investments for long-term value [6][8] - A $125 million share buyback program was announced, reflecting commitment to shareholders and confidence in growth prospects [9] Strategic Healthcare Assets - Armata, a portfolio company, is a market leader in bacteriophage therapeutics, with a 100% clinical cure rate in a Phase 2 trial for Staph aureus bacteremia [10] - The company is excited about Armata's plans to initiate a Phase 3 study, which could lead to significant market changes [11] Growth Opportunities - The therapeutic business is in a high growth period, with potential for both organic and inorganic growth [12] - The strategic healthcare assets are expected to provide asymmetric payoffs with beneficial risk-reward profiles [13] Product Updates - ZEVTERA, approved for treating bacterial infections, is in the early stages of market penetration with positive feedback from the medical community [15][16] - Zoliflodacin (NUZOLVENCE) is set for commercialization in the second half of the year, focusing on outpatient providers [18][19] - Peak sales expectations for IST products include: - GIAPREZA: $150 million potential, with $72 million in 2025 sales [23] - Zegdura: Expected to reach $150 million-$200 million, with $33 million in 2025 sales [25] - XERAVA: Stable revenue source with lower growth rates anticipated [26] - ZEVTERA: Expected to show good revenue trajectory in the second half of the year [27] - NUZOLVENCE: Total addressable market could be as large as $500 million [28] Underappreciated Aspects - Innoviva's ability to succeed in various economic environments due to strong cash flows and diversified business model [29] - Growth potential in strategic healthcare assets, particularly with Armata and other investments [31][32] Future Outlook - 2026 is anticipated to be an exciting year with multiple catalysts, including Armata's Phase 3 trial and potential Phase 2 readout from Syndeio [33][34] - Continued focus on growing the IST portfolio and launching new products [34][35]

Financial Highlights • Total revenue: Total revenue for the fourth quarter 2025 was $114.6 million, representing 25% growth compared to total revenue of $91.8 million for the fourth quarter 2024. Total revenue for the full year 2025 was $411.3 million, reflecting 15% growth compared to total revenue of $358.7 million for the full year 2024. Exhibit 99.1 Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress Durable royalties portfolio generated $58.4 million ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | (Mark One) | | | --- | --- | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2025 | | | or | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the transition period from to | | | Commission File No. 000-30319 | | | INNOVIVA, INC. | | | (Exact name of registrant as specified in its cha ...

Core Viewpoint - Innoviva, Inc. (NASDAQ:INVA) is highlighted as a promising small-cap stock with significant upside potential following the FDA approval of its antibiotic NUZOLVENCE® [1][2]. Group 1: FDA Approval and Product Details - The FDA approved NUZOLVENCE® (zoliflodacin) on December 12, which is a first-in-class, single-dose, oral antibiotic for treating uncomplicated urogenital gonorrhea in adults and pediatric patients aged 12 and older weighing at least 35 kg [2][4]. - The approval was based on results from a Phase 3 clinical trial, the largest ever conducted for a new treatment against Neisseria gonorrhoeae infection in high-prevalence regions across five countries [4]. Group 2: Market and Investment Insights - H.C. Wainwright updated Innoviva's price target to $46 from $45 while maintaining a Buy rating on the stock, indicating positive market sentiment following the FDA approval [1][2]. - Despite the potential of Innoviva as an investment, there are suggestions that certain AI stocks may offer greater upside potential with less downside risk [5].

Core Viewpoint - The FDA has approved NUZOLVENCE® (zoliflodacin), a first-in-class oral medication for treating uncomplicated urogenital gonorrhea in adults and pediatric patients aged 12 and older weighing at least 35 kg [1] Company Summary - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is responsible for the development and announcement of NUZOLVENCE [1] - The development of NUZOLVENCE was part of a private, not-for-profit collaboration [1] Industry Summary - The approval of NUZOLVENCE represents a significant advancement in the treatment options available for uncomplicated urogenital gonorrhea [1]